Hutchison China MediTech Limited (HCM): Price and Financial Metrics

Hutchison China MediTech Limited (HCM): $29.94

0.21 (+0.71%)

POWR Rating

Component Grades













Add HCM to Watchlist
Sign Up

Industry: China


of 50

in industry


  • Sentiment is the dimension where HCM ranks best; there it ranks ahead of 90.29% of US stocks.
  • The strongest trend for HCM is in Value, which has been heading up over the past 31 weeks.
  • HCM's current lowest rank is in the Quality metric (where it is better than 8.18% of US stocks).

HCM Stock Summary

  • Of note is the ratio of HUTCHMED (China) Ltd's sales and general administrative expense to its total operating expenses; just 12.72% of US stocks have a lower such ratio.
  • HCM's price/sales ratio is 18.64; that's higher than the P/S ratio of 89.1% of US stocks.
  • With a year-over-year growth in debt of 393.03%, HUTCHMED (China) Ltd's debt growth rate surpasses 96.86% of about US stocks.
  • Stocks that are quantitatively similar to HCM, based on their financial statements, market capitalization, and price volatility, are OCFT, TARO, AUMN, VNE, and NEON.
  • Visit HCM's SEC page to see the company's official filings. To visit the company's web site, go to

HCM Stock Price Chart Interactive Chart >

Price chart for HCM

HCM Price/Volume Stats

Current price $29.94 52-week high $43.94
Prev. close $29.73 52-week low $23.67
Day low $29.81 Volume 413,189
Day high $31.15 Avg. volume 315,284
50-day MA $32.79 Dividend yield N/A
200-day MA $33.63 Market Cap 5.18B

Hutchison China MediTech Limited (HCM) Company Bio

Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in China. The company was founded in 2000 and is based in Hong Kong, Hong Kong.

HCM Latest News Stream

Event/Time News Detail
Loading, please wait...

HCM Latest Social Stream

Loading social stream, please wait...

View Full HCM Social Stream

Latest HCM News From Around the Web

Below are the latest news stories about HUTCHMED (China) Ltd that investors may wish to consider to help them evaluate HCM as an investment opportunity.

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the upcoming 2022 ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022. The meeting will be held virtually and in person at the Moscone Center in San Francisco, California, US. Further details of the presenta

Yahoo | January 19, 2022

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, for the treatment of chronic adult primary immune thrombocytopenia (“ITP”) patients who have received at le

Yahoo | January 12, 2022

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 that also target the B-cell receptor (“BCR”) signaling pathway, and tazemetostat and HMPL-306 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) has initiated a Phase

Yahoo | January 10, 2022

HUTCHMED Included in FTSE Russell Indexes

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 19, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”) in its quarterly review, including the FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The inclusions come into effect on Monday, December 20, 2021. FTSE Russell is a global index leader that provid

Yahoo | December 20, 2021

Virtus AllianzGI International Small-Cap Fund Buys Alchip Technologies, Sojitz Corp, Bystronic ...

Investment company Virtus AllianzGI International Small-Cap Fund (Current Portfolio) buys Alchip Technologies, Sojitz Corp, Bystronic AG, Industrial & Infrastructure Fund Investment Corp, JMDC Inc, sells Marui Group Co, HELLA GmbH KGaA, OC Oerlikon Corp AG, Pfaffikon, Showa Denko KK, Open House Co during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Virtus AllianzGI International Small-Cap Fund.

Yahoo | December 11, 2021

Read More 'HCM' Stories Here

HCM Price Returns

1-mo -15.26%
3-mo -6.93%
6-mo -25.87%
1-year -9.79%
3-year 35.17%
5-year 115.55%
YTD -14.65%
2021 9.56%
2020 27.72%
2019 8.58%
2018 -41.43%
2017 190.49%

Continue Researching HCM

Want to see what other sources are saying about Hutchison China MediTech Ltd's financials and stock price? Try the links below:

Hutchison China MediTech Ltd (HCM) Stock Price | Nasdaq
Hutchison China MediTech Ltd (HCM) Stock Quote, History and News - Yahoo Finance
Hutchison China MediTech Ltd (HCM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8154 seconds.